Delivery Order HHSN272201600006I-75N93023F00001
Award Date
8/28/23
Potential Completion Date
12/31/24
Potential Value
$800K
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Alachua, FL 32615, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....
This is a delivery order award under the Preclinical Services for Biopharmaceutical Product Development Indefinite Delivery Indefinite Quantity (IDIQ) contract, issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The $816,039.00 award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) is for stability testing of NTM-1632 and NTM-1633. This award does not...
This is a federal contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.), a technology-focused biomanufacturing company, for a Clinical Development Phase 2 Study. The contract is valued at $107,935,344.00 and has an ultimate completion date of February 29, 2028. The contract was awarded on January 4, 2022 by the Joint Program Executive Office for Chemical and Biological Defense, a component of the U.S. Department of the Army. No set-aside designation was...
This is a definitive contract awarded by the Department of the Army's Joint PEO Chemical and Biological Defense, a defense agency, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $366,290,602.35 cost-plus-fixed-fee contract is for the Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Capability, with a period of performance through October 31, 2023. As a prime contractor, Resilience has provided a range of goods and services related...
This is a $1,040,997.51 cost-plus-fixed-fee definitive contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The contract is for PMR (Performance Monitoring and Reporting) and PMC (Performance Measurement Criteria) services, with a period of performance ending on July 31, 2021. Resilience, a technology-focused biomanufacturing company, has previously...
This is a $6,821,012.21 Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for the development of a broad spectrum monoclonal antibody-based therapeutic for botulism, a biological threat. The contract has no set-aside designation and the ultimate completion date is September...
This is a $190,241,861.21 Other Transaction Agreement awarded by the Department of the Army's Joint PEO Chemical and Biological Defense to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.), a technology-focused biomanufacturing company. The contract does not have a set-aside designation. The agreement, awarded on February 21, 2020, supports the development and manufacturing of medical countermeasures against biological threats and COVID-19. Resilience has provided...
This is a $162,950,791.20 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Leidos, Inc. Research And Development Division. The contract is for biomedical (basic) research and development services, and does not have a set-aside designation. The contract is associated with larger contract vehicles, including the One Acquisition Solution for Integrated Services (OASIS) and Alliant II Governmentwide...
This is a task order award under a broader Indefinite Delivery/Indefinite Quantity (IDIQ) contract with a ceiling value of $1,429,082.54. The prime contractor is Battelle Memorial Institute, a large non-profit research and development organization. The contracting agency is the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The task order is for $132,813 and has an ultimate completion date of April 17,...